- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01899040
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
May 4, 2018 updated by: Scion NeuroStim
This is a randomized, blinded study designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of episodic migraine headaches.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
81
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Canterbury
-
Kent, Canterbury, United Kingdom, CT2 7NP
- Kent University
-
-
-
-
California
-
San Diego, California, United States, 92134
- Naval Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Michigan Headache and Neurological Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27516
- Carolina Headache Institute
-
Durham, North Carolina, United States, 27705
- Duke University
-
Greensboro, North Carolina, United States, 27405
- Headache Wellness Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- The patient must have been diagnosed with episodic Migraine Headache at least 6 months prior to entering into the Study, consistent with the International Headache Classification of Headache Disorders-II (ICHD-II) guidelines.
- The patient must have a history of at least three consecutive months of stable Migraine Headaches prior to entering the Study. The patients will not have had changes in medication usage for the three Months leading up to the Study, nor will they introduce new medications during the Study period. Patients will satisfy these criteria: On a Monthly basis, at least four, and not more than a total of fourteen (4-14), Headache Days (Pain Score between one and ten) of which between four and nine (4-14) are Migraine Headache Days
- The patient must not have failed on more than two classes of properly administered prophylactic pharmaceutical therapies for migraine headache. The patient may be on a single migraine prophylactic as long as the dosage has not been altered within 3 months of starting the study and the dosage must not be altered for the duration of the study.
- The Investigator must have confidence in the patient's ability to reliably use the Experimental Device and promptly complete the Daily Headache Diary forms. The Daily Headache Diary will be completed from the beginning of the Pre-Treatment Baseline Period through the end of the Pivotal Study.
EXCLUSION CRITERIA:
Individuals who:
- are pregnant
- have a history of cardiovascular disease
- work night shifts
- have been diagnosed with vestibular migraine
- have been diagnosed with migraine with aura
- have menstrual migraine exclusively
- have been diagnosed with post-traumatic migraine
- have a history of unstable mood disorder or unstable anxiety disorder
- use a hearing aid
- have a cochlear implant
- have chronic tinnitus
- have temporomandibular joint disease
- have been diagnosed with traumatic brain injury
- have been diagnosed with neurological disease other than Headaches
- have a diagnosed vestibular dysfunction
- abuse alcohol or other drugs
- are experiencing medication overuse Headaches (individuals with respect to whom the Investigator is concerned that analgesic abuse is involved based on the ICHD-II guidelines).
- are less than 18 years old or greater than 65 years old
- have had eye surgery within the previous three months or ear surgery within the previous six months
- have active ear infections or a perforated tympanic membrane
- have participated in another clinical trial within the last 30 days or are currently enrolled in another clinical trial
- are using Botox treatments for migraines
- Though not excluded, patients taking anti-histamines or anti-nausea drugs will be encouraged not to take such medications within four hours prior to using the Device. The Investigator should review other medications taken by the patient with properties that mimic anti-nausea or anti-dizziness drugs as these may reduce responsiveness to stimulation. Such medications should also be avoided within four hours prior to a treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active device
A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites.
The Device will be used twice daily.
|
|
Placebo Comparator: placebo device
A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites.
The Device will be used twice daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of monthly migraine headache days
Time Frame: after 84 days of Device use
|
During the third Month of Device use, the average total number of Monthly Migraine Headache Days will be lower than comparable averages derived from the Pre-use Baseline Period
|
after 84 days of Device use
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of monthly migraine headache days (reduction by by 50% or more)
Time Frame: after 84 days of Device use
|
A reduction of 50% or more in monthly Migraine Headache Days during the third Month of Device use as compared with the Pre-use Baseline Period.
|
after 84 days of Device use
|
Total monthly pain score
Time Frame: after 84 days of Device use
|
During the third Month of Device use, the average Total Monthly Headache Pain Scores will be lower than comparable averages derived from the Pre-use Baseline Period.
|
after 84 days of Device use
|
Mood and cognition measures - Change in mood scores
Time Frame: after 84 days of Device use
|
A patient's Pre-use Baseline Period mood scores will be compared with those at the end of the Device use period.
Mood scores will be assessed for: a decline, no change, or an improvement.
|
after 84 days of Device use
|
Verify the absence of material dizziness
Time Frame: after 84 days of Device use
|
The principal safety endpoint for the Study is to verify the absence of material dizziness, with the associated risk of falls, as a consequence of using the Device.
|
after 84 days of Device use
|
Mood and cognition measures - Change in cognitive speed scores
Time Frame: after 84 days of Device use
|
A patient's Pre-use Baseline Period cognitive speed scores will be compared with those at the end of the Device use period.
Cognitive speed scores will be assessed for: a decline, no change, or an improvement.
|
after 84 days of Device use
|
Mood and cognition measures - Change in memory scores
Time Frame: after 84 days of Device use
|
A patient's Pre-use Baseline Period memory scores will be compared with those at the end of the Device use period.
Memory scores will be assessed for: a decline, no change, or an improvement.
|
after 84 days of Device use
|
Use of acute medications - change in number of treated headaches
Time Frame: after 84 days of device use
|
During the third month of device use, the number of abortive medications taken will be less than the number taken in the baseline month
|
after 84 days of device use
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Lesco Rogers, MD, Scion NeuroStim
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
June 29, 2013
First Submitted That Met QC Criteria
July 10, 2013
First Posted (Estimate)
July 15, 2013
Study Record Updates
Last Update Posted (Actual)
May 11, 2018
Last Update Submitted That Met QC Criteria
May 4, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNS-MIG-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Headache, Episodic
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Mayo ClinicRecruiting
-
Kuang Tien General HospitalRecruitingThe Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic MigraineEpisodic MigraineTaiwan
-
AbbVieEnrolling by invitationEpisodic MigraineUnited States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
-
AmgenNovartisCompletedEpisodic MigraineBelgium, United States, Spain, Czechia, Finland, United Kingdom, Israel, Ireland, Netherlands, Argentina, Austria, France, Germany, Greece, Italy, Poland, Portugal, Slovakia
-
AllerganCompletedEpisodic MigraineUnited States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
-
Dr. Reddy's Laboratories LimitedCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.NCGS, Inc.CompletedEpisodic Migraine HeadacheUnited States
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)Completed
Clinical Trials on neuromodulation for episodic migraine headache
-
Scion NeuroStimTerminatedInterventionUnited States, United Kingdom
-
Beijing Tiantan HospitalNot yet recruitingMigraine | Headache Disorders, Primary | Medication Overuse Headache | Tension-Type Headache | New Daily Persistent Headache | Trigeminal Autonomic Cephalalgia
-
University of AlbertaNot yet recruitingHemorrhagic Stroke | Reversible Cerebral Vasoconstriction Syndrome | Cerebral Venous Sinus Thrombosis | Headache, Migraine | Stroke (CVA) or TIA | Botulinum Toxins, Type A | Carotid Dissection Artery | Vertebral Dissection ArteryCanada
-
Henry Ford Health SystemMichigan State University; University of Kansas; Detroit Recovery Project INCRecruiting
-
Samsung Medical CenterUnknownCluster Headache | Disease CourseKorea, Republic of
-
Janssen Korea, Ltd., KoreaCompleted
-
Headache Sciences IncorporatedRecruitingMigraine | Tension-Type Headache | Chronic MigraineCanada
-
University of CologneUniversity Hospital of Cologne; Bethanien Krankenhaus gGmbHCompletedHeart Failure | Neoplasms | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Respiratory Insufficiency | Lung Diseases, Interstitial | Palliative Care | Dyspnea | Palliative Medicine | BreathlessnessGermany
-
VA Connecticut Healthcare SystemTerminated